July 25, 2012 (London, United Kingdom) — The UK National Institute for Health and Clinical Excellence (NICE) concludes that the oral factor Xa inhibitor rivaroxaban (Xarelto, Bayer) is a cost-effective alternative to warfarin for treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism. It made the statement today [1] on the release of its final guidance document recommending the drug for that indication [2].
The purpose of the NICE document on rivaroxaban, already technically on the market in the UK for the DVT indications, is to establish that it is reimbursable and guide how it is to be reimbursed.
As covered in detail by heartwire , the agency's decision was based largely on positive results from the EINSTEIN-DVT and EINSTEIN-Extension trials--as was the oral factor Xa inhibitor's market approval for DVT by regulators in the European Union in December 2011.
Heartwire from Medscape © 2012 Medscape, LLC
Cite this: Rivaroxaban Gets NICE Thumbs-Up for DVT - Medscape - Jul 26, 2012.
Comments